Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials

被引：4
|
作者：
Zhang, Xi [1 ]
Ran, Yu-ge [1 ]
Wang, Kun-jie [2 ]
机构：
[1] Hebei Univ, Affiliated Hosp, Dept Radiat Oncol, Baoding 071000, Peoples R China
[2] Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding 071000, Peoples R China
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 12期
关键词：
cancer; meta-analysis; mTOR inhibitors; pneumonitis; RENAL-CELL CARCINOMA; PHASE-III TRIAL; DRUG-RELATED PNEUMONITIS; MAMMALIAN TARGET; DOUBLE-BLIND; BREAST-CANCER; NONINFECTIOUS PNEUMONITIS; NEUROENDOCRINE TUMORS; INTERFERON-ALPHA; RAPAMYCIN MTOR;
D O I：
10.2217/fon-2016-0020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancer patients. Materials & methods: PubMed, EMBASE and oncology conference proceedings were searched for relevant studies. Results: A total of 8377 patients from 16 randomized controlled trials were included. The incidence of severe pneumonitis associated with mTORi was 1.7% (95% CI: 1.1-2.5%). The use of mTORi significantly increased the risk of severe pneumonitis compared with controls (odds ratio: 3.36; 95% CI: 2.20-5.12). The analysis was stratified for drug types, tumor types, controlled therapy and mTORi-based regimens, but no significant differences in odds ratios were observed. Conclusion: mTORi significantly increase the risk of severe pneumonitis in cancer patients.
引用
收藏
页码：1529 / 1539
页数：11
相关论文
共 50 条
  • [1] Incidence and risk of rash to mTOR inhibitors in cancer patients a meta-analysis of randomized controlled trials
    Shameem, Raji
    Lacouture, Mario
    Wu, Shenhong
    ACTA ONCOLOGICA, 2015, 54 (01) : 124 - 132
  • [2] Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
    Zhou, Jian xin
    Feng, Li jin
    Zhang, Xi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3009 - 3017
  • [3] Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database
    Ma, Zhuo
    Sun, Ximu
    Zhao, Zhixia
    Lu, Wenchao
    Guo, Qixiang
    Wang, Shihao
    You, Jiwen
    Zhang, Yuhui
    Liu, Lihong
    GYNECOLOGIC ONCOLOGY, 2021, 162 (02) : 496 - 505
  • [4] Risk of Anemia Attributable to Everolimus in Patients with Cancer: A Meta-analysis of Randomized Controlled Trials
    Shameem, Raji
    Hamid, Muhammad Saad
    Wu, Shenhong
    ANTICANCER RESEARCH, 2015, 35 (04) : 2333 - 2340
  • [5] Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials
    Qiao, Longwei
    Liang, Yuting
    Mira, Ranim R.
    Lu, Yaojuan
    Gu, Junxia
    Zheng, Qiping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (10): : 3333 - 3343
  • [6] Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials
    Li, Jing
    Zhang, Zhifeng
    JOURNAL OF CHEMOTHERAPY, 2021, 33 (07) : 452 - 461
  • [7] Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials
    Li, Xuyuan
    Zhu, Sujuan
    Hong, Chaoqun
    Cai, Haoquan
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (03) : 555 - 562
  • [8] Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
    Hang, Xiao Feng
    Xu, Wen Sheng
    Wang, Jun Xue
    Wang, Lei
    Xin, Hai Guang
    Zhang, Rui Qi
    Ni, Wu
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (06) : 613 - 623
  • [9] Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials
    Li, Jing
    Gu, Jian
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 134 : 31 - 38
  • [10] Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials
    Wang, Chengyuan
    Li, Jing
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (03) : 571 - 584
12345